Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Current Deferred Revenue (2018 - 2025)

10x Genomics (TXG) has disclosed Current Deferred Revenue for 8 consecutive years, with $34.4 million as the latest value for Q4 2025.

  • Quarterly Current Deferred Revenue rose 3.61% to $34.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $34.4 million through Dec 2025, up 3.61% year-over-year, with the annual reading at $34.4 million for FY2025, 3.61% up from the prior year.
  • Current Deferred Revenue hit $34.4 million in Q4 2025 for 10x Genomics, up from $33.0 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $34.4 million in Q4 2025 to a low of $5.4 million in Q1 2022.
  • Historically, Current Deferred Revenue has averaged $18.0 million across 5 years, with a median of $12.7 million in 2022.
  • Biggest five-year swings in Current Deferred Revenue: fell 10.92% in 2022 and later surged 201.62% in 2024.
  • Year by year, Current Deferred Revenue stood at $7.7 million in 2021, then skyrocketed by 43.5% to $11.0 million in 2022, then soared by 99.09% to $22.0 million in 2023, then surged by 51.16% to $33.2 million in 2024, then rose by 3.61% to $34.4 million in 2025.
  • Business Quant data shows Current Deferred Revenue for TXG at $34.4 million in Q4 2025, $33.0 million in Q3 2025, and $32.7 million in Q2 2025.